- Research
- Open access
- Published:
A retrospective analysis of transudative pleural effusion due to fibrosing mediastinitis
Journal of Cardiothoracic Surgery volume 19, Article number: 467 (2024)
Abstract
Background
Pleural effusion caused by fibrosing mediastinitis is rarely reported. This study aimed to summarize the clinical manifestations, diagnosis and treatment of transudative pleural effusion due to fibrosing mediastinitis.
Methods
Medical records and follow-up data of 7 patients with transudative pleural effusion due to fibrosing mediastinitis in Beijing Chaoyang Hospital between May 2014 and Feb 2018 were retrospectively analyzed.
Results
These patients included 4 males and 3 females, with an average age of (64 ± 9) years. There were 3 left-sided effusions, 2 right-sided effusions and 2 bilateral effusions. Previous or latent tuberculosis was found in 6 patients. Pulmonary hypertension was indicated by echocardiography in all the 7 patients. Computed tomography pulmonary angiography (CTPA) of all the 7 cases showed increased soft tissue images visible in the mediastinum and bilateral hilus, different degrees of stenosis or occlusion in the pulmonary artery and pulmonary vein. In addition, 4 cases were found of right middle lobe atelectasis with a mediastinal window setting. There was interstitial pulmonary edema on the side of pleural effusion with a lung window setting. All the 7 patients were treated with intermittent drainage of pleural effusion combined with diuretic therapy. Five patients were treated with antituberculosis therapy. Up to now, two patients died of right heart failure and respiratory failure after 2 and 16 months respectively; The remaining 5 patients were still in follow up.
Conclusion
Fibrosing mediastinitis can lead to pulmonary vein stenosis or occlusion, and thus cause transudative pleural effusion, which can be detected by CTPA. Pulmonary hypertension, long time of cough, and a history of tuberculosis are common in these patients. The common therapy is intermittent drainage of pleural effusion combined with diuretic therapy.
Introduction
Pleural effusion is a common clinical problem caused by different underlying diseases, such as cancer, congestive heart failure, hepatic hydrothorax, pulmonary embolism, nephrotic syndrome, etc. [1, 2]. The most common cause of malignant pleural effusion is lung cancer, followed by breast cance [1].
Fibrosing mediastinitis is often caused by the proliferation of acellular collagen and fibrous tissue within the mediastinum, and manifested with obstruction or compression of central airways, esophagus, or pulmonary veins or arteries [3]. The pulmonary vessels and tracheal bronchus stenosis or occlusion in patients of fibrosing mediastinitis often result in pulmonary hypertension and atelectasis [3, 4]. The focal type of fibrosing mediastinitis usually manifests as a localized, calcified mass in the paratracheal or subcarinal regions of the mediastinum or in the pulmonary hila under Computed tomography pulmonary angiography (CTPA) or magnetic resonance observations; The clinical images of the diffuse type show a diffusely infiltrating, which often noncalcified mass that affects multiple mediastinal compartments [3]. When acute mediastinitis occurs, high morbidity and mortality follow [4].
The transudative pleural effusion due to fibrosing mediastinitis is rarely reported. In a previous report, a 70-year-old man who was finally diagnosed of fibrosing mediastinitis combined with transudative pleural effusion was misdiagnosed of tuberculous pleurisy with his specified breathlessness and refractory left pleural effusion [5]. This report by Yang et al. [5]. indicated transudative pleural effusions of might be caused by the rare disease-fibrinous mediastinitis. Therefore, fibrosing mediastinitis combined with transudative pleural effusion requires careful diagnosis and etiological differentiation [5].
Therefore, we reviewed and analyzed the medical records and follow-up data of the 7 patients with transudative pleural effusion due to fibrosing mediastinitis in our hospital, in order to summarize the clinical manifestations, diagnosis and treatment for these rare cases.
Methods
Subjects
A retrospective analysis was made in 7 patients with transudative pleural effusion due to fibrosing mediastinitis in Beijing Chaoyang Hospital between May 2014 and Feb 2018. These patients had been admitted to hospital for transudative pleural effusion. The clinical manifestation, lab test, imaging analysis, pulmonary function, echocardiography, bronchoscopy, pulmonary artery angiography, and treatments were reviewed. The follow-up data were obtained by reviewing of the medical records and the telephone calls to patients and their families. The follow up ended in December of 2022.
This study was approved by the Medical Ethics Committee of our hospital. The written informed consents were obtained from the patients and the patients’ family members. The data in this study comply with the patient confidentiality principles.
Diagnostic criteria for transudates
According to Light’s criteria [6]: (1) The ratio of pleural fluid protein to serum protein is greater than 0.5; (2) The ratio of pleural fluid Lactate dehydrogenase (LDH) and serum LDH is greater than 0.6; (3) Pleural fluid LDH is two-thirds greater than the normal upper limit for serum. Transudative pleural effusions meet none of these three characteristics. Etiology of the transudative pleural effusion had been confirmed of fibrosing mediastinitis, and excluded congestive heart failure, cirrhosis, nephrotic syndrome, hypoalbuminemia and other common diseases that can cause transudative pleural effusion.
Diagnosis of fibrosing mediastinitis
The CTPA characteristics of fibrosing mediastinitis was either a diffuse or localized soft-tissue mediastinal mass. Typically, the soft-tissue mass obliterates normal mediastinal fat planes and causes compression of adjacent structures, including pulmonary vessels, trachea, esophagus, pericardium and heart, nerves and pleura, and even lung tissue [7]. The diagnosis of fibrosing mediastinitis was confirmed by CTPA in this study.
Statistical analysis
SPSS Statistics version 22.0 (IBM, USA) was used in this study. Data were presented as mean ± standard deviation or number with percentage. Descriptive statistical methods were used for data analysis. Missing data was excluded for this study.
Results
Clinical manifestations
A total of 7 patients were studied, and the clinical manifestations of these patients were shown in Table 1. These patients included 4 males and 3 females, with an average age of (64 ± 9) years. The main symptoms were cough (7/7), breathlessness (7/7), blood in phlegm (1/7), and leg edema (2/7). The shortest time from onset of pleural effusion to making a definitive diagnosis was 40 days, and the longest was 8 months. The medium diagnosis time was 4.6 ± 2.6 months. There were 3 left-sided effusions, 2 right-sided effusions and 2 bilateral effusions. Six patients had a history of tuberculosis and one with a history of occupational dust exposure (iron and zinc).
In Supplemental Digital Content, the details about physical characteristics and pathologic indicators of each patient were displayed.
Results of lab and assistant examinations
The results of lab and assistant examinations were shown in Table 2. In the 7 patients, the erythrocyte sedimentation rate was 12.7 ± 7.1 mm/h, purified protein derivative tests were all negative, and the T-SPOT.TB test was negative in 4 cases, and the other 3 cases were positive. N-terminal pro-brain natriuretic peptide was from 10 to 3957 pg/ml. Five patients had type I respiratory failure, and two had hypoxemia.
Pulmonary hypertension was suggested by echocardiography in all the 7 patients, and pulmonary artery systolic pressure was 74.1 ± 27.6 mmHg. The patient with the highest pulmonary hypertension also had right ventricular enlargement, right ventricular hypertrophy, and decreased right ventricular wall motion. Pulmonary function showed obstructive ventilatory dysfunction in 3 cases and mixed ventilatory dysfunction in one case.
Bronchoscopy of 3 patients showed airway distortion, multiple stenosis or occlusion, and scattered foci of black spots in the airway mucosa. Two cases were examined by medical thoracoscopy, one case had no positive result, and the other case (case 5) showed scattered foci of black nodules in the visceral, parietal and diaphragmatic pleura. A diagnostic biopsy of the nodules suggested a granulomatous inflammation induced by small foreign bodies.
CTPA of 7 cases (Table 3) showed that increased soft tissue images were visible in the mediastinum and bilateral hilus, different degrees of stenosis or occlusion in the pulmonary artery and pulmonary vein (Fig. 1), and 4 cases with right middle lobe atelectasis with a mediastinal window setting; and there was interstitial pulmonary edema on the side of pleural effusion with a lung window setting (Fig. 2). Pulmonary arteriography was performed in 4 cases, indicating multiple pulmonary artery stenosis and/or occlusion during the artery period, and lung perfusion defect and pulmonary vein involvements without imaging during the vein period (Fig. 3).
Treatment and follow-up
All 7 patients were treated with intermittent drainage of pleural effusion combined with diuretic therapy. Five patients were treated with antituberculosis therapy. Clinical follow-up was available in all the 7 patients, ranging from 2 to 47 months. Two patients died of right heart failure and respiratory failure at 2 (case 1) and 16 months (case 2) respectively after the diagnosis. The remaining 5 patients were treated with oral diuretics after discharge without repeating drainage of pleural fluid. They still had a small to moderate amount of pleural effusion that can be tolerated and received oral-take diuretics intermittently. They are still in follow-up.
Discussion
The first question in assessing a patient with a pleural effusion is whether the effusion is a transudate or an exudate. The distinction between transudates and exudates can help to determine the underlying cause of a pleural effusion [1, 2]. Light’s criteria are the most used to separate transudates from exudates [6]. However, Light’s criteria on pleural effusions to classify transudative or exudative may have a misclassification rate of 10–20% [8, 9]. Pleural fluid met Light’s criteria for a transudate throughout in 6 of 7 patients. However, in the case 5 patient, LDH level (case 5) initially met exudate criteria, while in the later stage, the characteristics of pleural fluid were fully accordant with a transudate. We noted that only LDH met exudate at the early stage, whereas other parameters such as total protein, total nucleated cell and differentials counts were not typically consistent with exudate. While a large amount of pleural effusion (800–1200 mL per day) was drained daily for nearly 4 months, serum total protein and albumin were not reduced, indicating no obvious loss of protein. A protein gradient between the serum protein and pleural fluid was 3.24 g/dL at the early stage, so the pleural fluid initially should be a transudate.
The proliferation of fibrous tissue within the mediastinum is the obvious sign of fibrosing mediastinitis, which may lead to compression or obstruction of vital mediastinal structures [3, 4]. The most common cause for fibrosing mediastinitis is infection, which may be resulted from prior granulomatous infections [4]. Other causes include neoplasms, radiation therapy, immune-related diseases, traumatic hemorrhage, and drugs [3, 4]. An immune-mediated hypersensitivity response is presented to histoplasma capsulatum infection in most cases [4]. The pathogenesis of extensive fibrosing mediastinitis in Chinese patients is reported to be associated with tuberculosis (TB) infections [10]. In this study, 6 of 7 patients reported a history of tuberculosis. And in the TB test, 3 cases were still positive when they admitted to the hospital. However, it was difficult to get tissue from these sites including mediastinum and hilus pulmonic, all patients had no pathological diagnosis in this study, which is a limitation for these rare reports.
Most cases of fibrosing mediastinitis can be diagnosed based on clinical and radiographic criteria. A report summarized the chest radiographic imaging of fibrosing mediastinitis, that invasive, localized, and frequently calcified right-sided mediastinal masses were mostly revealed in the patients of this disease [11]. Typically, the soft-tissue mass obliterates normal mediastinal fat planes and causes compression of adjacent structures, including pulmonary vessels, trachea, esophagus, pericardium and heart, nerves and pleura, and even lung tissue, especially, pulmonary vein, because of the thin wall of the vein [7, 12]. In this report, the common features of the 7 patients with CTPA were that the soft tissue of the mediastinum and bilateral hilar markedly enlarged, accompanied by varying degrees of stenosis or occlusion in pulmonary artery and pulmonary venous, with or without atelectasis.
Pulmonary vein stenosis or occlusion due to fibrosing mediastinitis can result in an increase in hydrostatic pressure, which is the main cause of transudative pleural effusion. The imaging of pulmonary vein stenosis or occlusion can directly be seen on a CT angiogram of the chest [7, 12]. In addition, interlobular septal thickening and patchy ground glass opacities suggestive of interstitial pulmonary edema in lung window indirectly suggest pulmonary vein stenosis or occlusion. On the other hand, pulmonary angiography can help to diagnose pulmonary vein stenosis or occlusion. During vein period, involved pulmonary veins without imaging or thin can be seen. Meanwhile, the corresponding pulmonary field perfusion defect can also be found [7, 12]. In addition, pulmonary hypertension may severe as a common complication of the disease [13]. This study indicated pulmonary hypertension by echocardiography in all the 7 patients.
Treating the transudate due to fibrosing mediastinitis is particularly challenging. The underling diseases must be solved [1, 4]. Catheter-based intervention for fibrosing mediastinitis had an overall poor prognosis [14]. For those patients suffering from pulmonary vein stenosis or occlusion, catheter-based intervention, such as balloon angioplasty with or without a stent, is the potential treatment option, but the prognosis is poor. The Mayo Clinic reported eight patients with pulmonary vein stenosis or occlusion underwent balloon angioplasty or stents placed [14]. Four out of 8 patients died within four weeks of their first pulmonary vein intervention as reported in a previous study [14]. Therapy with antifungal, anti-inflammatory agents and antituberculosis provides little benefit; Glucocorticoids also do not appear to be beneficial [4, 10, 11, 15]. Therapy is recommended to be palliative, and the intermittent drainage of pleural effusion in combination with diuretic therapy is minimally invasive and inexpensive for the patient with thoracentesis drainage [16]. Previous report also showed effective drainage of pleural effusion in patients with pleural effusion followed by few complications [17]. In this study, all the 7 patients had not received pulmonary vein interventional treatment because of high risk and high cost. The causes of death of 2 patients during the follow-up were related to right heart failure. The other 5 patients were in stable condition and were still under follow-up.
This study was limited for its small sample size due to the rare occurrence of fibrosing mediastinitis. The incidence of pleural effusion due to pulmonary vein stenosis caused by fibrosing mediastinitis is very low, so that the sample size was small. More samples need to be collected to better understanding this disease in future.
In conclusion, fibrosing mediastinitis is a rare cause of transudative pleural effusion. For the patient with transudative pleural effusion who had a history of tuberculosis; or who had a long time of cough, phlegm with blood, and short of breath; or whose echocardiography suggests pulmonary hypertension; and whose radiographic imaging reveals the presence of interstitial pulmonary edema on the side of pleural effusion, with or without atelectasis, fibrosing mediastinitis should be considered. Fibrosing mediastinitis can be detected by CTPA. There is no guideline for therapy now.
Data availability
The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
References
Jany B, Welte T. Pleural effusion in adults-etiology, diagnosis, and treatment. Dtsch Arztebl Int. 2019;116(21):377–86.
Kinasewitz GT. Transudative effusions. Eur Respir J. 1997;10(3):714–8.
Rossi SE, McAdams HP, Rosado-de-Christenson ML, Franks TJ, Galvin JR. Fibrosing mediastinitis. Radiographics. 2001;21:737–57.
Lin J, Jimenez CA. Acute mediastinitis, mediastinal granuloma, and chronic fibrosing mediastinitis: a review. Semin Diagn Pathol. 2022;39(2):113–9.
Yang S, Wang J, Li J, Huang K, Yang Y. Refractory pleural effusion as a rare complication of pulmonary vascular stenosis induced by fibrosing mediastinitis: a case report and literature review. J Int Med Res. 2021;49:3000605211010073.
Light RW, Macgregor MI, Luchsinger PC, Ball WC Jr. Pleural effusions: the diagnostic separation of transudates and exudates. Ann Intern Med. 1972;77:507–13.
Sherrick AD, Brown LR, Harms GF, Myers JL. The radiographic findings of fibrosing mediastinitis. Chest. 1994;106:484–9.
Gautam S, K C SR, Bhattarai B, et al. Diagnostic value of pleural cholesterol in differentiating exudative and transudative pleural effusion. Ann Med Surg (Lond). 2022;82:104479.
Romero S, Martinez A, Hernandez L, et al. Light’s criteria revisited: consistency and comparison with new proposed alternative criteria for separating pleural transudates from exudates. Respiration. 2000;67:18–23.
Hu Y, Qiu JX, Liao JP, Zhang H, Jin Z, Wang GF. Clinical manifestations of Fibrosing Mediastinitis in Chinese patients. Chin Med J (Engl). 2016;129:2697–702.
Peikert T, Colby TV, Midthun DE, et al. Fibrosing mediastinitis: clinical presentation, therapeutic outcomes, and adaptive immune response. Medicine (Baltim). 2011;90:412–23.
Pujitha V, Pandey NN, Arvind B, Kumar S. Idiopathic focal fibrosing mediastinitis with unilateral pulmonary arterial and venous involvement. J Card Surg. 2022;37:5466–7.
Sonsoz MR, Atamaner O, Inan D, Kilicgedik A. A rare cause of pulmonary hypertension: idiopathic fibrosing mediastinitis obstructing right pulmonary artery and pulmonary veins. Echocardiography. 2023;40:143–6.
Ponamgi SP, DeSimone CV, Lenz CJ, et al. Catheter-based intervention for pulmonary vein stenosis due to fibrosing mediastinitis: the Mayo Clinic experience. Int J Cardiol Heart Vasc. 2015;8:103–7.
Mathisen DJ, Grillo HC. Clinical manifestation of mediastinal fibrosis and histoplasmosis. Ann Thorac Surg. 1992;54:1053–7. discussion 1057-8.
Penz E, Watt KN, Hergott CA, Rahman NM, Psallidas I. Management of malignant pleural effusion: challenges and solutions. Cancer Manag Res. 2017;9:229–41.
Pollak JS, Burdge CM, Rosenblatt M, Houston JP, Hwu WJ, Murren J. Treatment of malignant pleural effusions with tunneled long-term drainage catheters. J Vasc Interv Radiol. 2001;12:201–8.
Acknowledgements
Not applicable.
Funding
Not applicable.
Author information
Authors and Affiliations
Contributions
YXY contributed to conception and design of the research; YXY, LA, ZHM, and HZS contributed to the acquisition of data. YXY and YHY did the analysis and interpretation of the data and the statistical analysis. LA, ZHM, and HZS validated the data. All authors contributed to the writing of the manuscript and the critical revision of the manuscript. All authors have read and approved the final version of the manuscript for publication.
Corresponding author
Ethics declarations
Ethics approval and consent to participate
This study was approved by the Medical Ethics Committee of our hospital. The written informed consents were obtained from the patients and the patients’ family members. The data in this study comply with the patient confidentiality principles.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no relevant financial or non-financial interest to disclose.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Yu, YX., An, L., Ma, ZH. et al. A retrospective analysis of transudative pleural effusion due to fibrosing mediastinitis. J Cardiothorac Surg 19, 467 (2024). https://doi.org/10.1186/s13019-024-02972-9
Received:
Accepted:
Published:
DOI: https://doi.org/10.1186/s13019-024-02972-9